Navigation Links
Cervical Retractor

ProductsCervical Retractor
Company Medicon eG
Item Cervical Retractor
Features 
Description Cervical Tissue Retractor 13 cm - 5 1/8, one blunt prong, 13 mm deep.
Info Medicon eG
Customer Service: +49 (0) 74 62 / 20 09-0

Related medicine products :

1. Cervical Retractor Handle - Large
2. Cervical Retractor Handle - Small
3. Codman Cervical Retractor
4. Cloward Cervical Retractor
5. Scoville Cervical Disc Retractor
6. Cervical Retractor With Post
7. Cervical Retractor With Double Finger Hold
8. Cervical Distraction Screw Retractor Blade
9. Caspar Cervical Retractor (Lamina Spreader)
10. Occipito-Cervical System
11. Songer Cable Cervical Thoracic System
... IMMULITE 2500 is a high-throughput immunoassay ... ,of the IMMULITE 2000 with the important ... technology ,allows assays to be designed for ... times. ,This allows for critical assays such ...
... System from KUBTEC is a dual capability system ... dimensional representation of the specimen under test. While ... X-ray images, the micro focus source also allows ... in standard 2D images. The 100 mm x ...
... The Duet Logic G|2 Provides Microsoft ... and reporting for clinics where logic, ... Medtronic diagnostic system is designed with ... physicians to combine different diagnostic tools ...
... experience in the field of Urodynamics, Albyn Medical ... Our new chair is manufactured from the highest ... studies can be improved considerably if the patient ... and this aspect was given a high priority ...
Medicine Products:
(Date:4/21/2015)... (PRWEB) April 21, 2015 Invictus ... a prestigious Illinois university for a second innovative ... (NICUs) more conducive to newborn infants’ cognitive development. ... three NICU problems we have identified through extensive ... professionals,” said George Hutchinson, Invictus Medical’s Chief Technology ...
(Date:4/21/2015)... San Diego, CA (PRWEB) April 21, 2015 ... owner of SunGrubbies.com. “Doesn’t every mother want to look younger ... sun protection is the first line of defense. ... spots that are the evidence of too much time spent ... not the only reason to cover up. The dangers ...
(Date:4/20/2015)... 20, 2015 Heritage Woods of Centralia, ... Open House and Dine-and-Dash Spaghetti Dinner from 4 p.m. ... which is located in Centralia, Illinois, houses senior living ... low-income adults 55 and older. , Guests are invited ... supportive living options for seniors. After the tours, they ...
(Date:4/20/2015)... 2015 Using Quality by Design to ... and Improve Compliance , **FDAnews Webinar**, May 7, 2015 ... , The life sciences industries are going through ... more with less. Mergers, acquisitions, the patent cliff ... ways to speed up production while still maintaining quality ...
(Date:4/20/2015)... Reality show stars, food, fashion and fun ... annual Michigan International Women’s Show, April 30 - May ... lots to see and do from enjoying a makeover ... gifts,” said Beth Anderson, executive show manager of Southern ... appearances from Randy Fenoli of ‘Say Yes to the ...
Breaking Medicine News(10 mins):Health News:Invictus Medical Secures Rights to Second Promising New NICU Technology 2Health News:Sun’s the Word this Mother’s Day Say’s SunGrubbies.com, a Leading Retailer of Sun Protection Products 2Health News:Heritage Woods of Centralia Senior Living Community to Host Open House and Spaghetti Dinner 2Health News:FDAnews Announces — Using Quality by Design to Improve Manufacturing: How Sponsors and CMOs Speed Production and Improve Compliance Webinar, May 7, 2015 2Health News:FDAnews Announces — Using Quality by Design to Improve Manufacturing: How Sponsors and CMOs Speed Production and Improve Compliance Webinar, May 7, 2015 3Health News:Perfect Girls Day Out at Michigan International Women’s Show Opening Thursday, April 30 in Novi Presented by Southern Shows 2Health News:Perfect Girls Day Out at Michigan International Women’s Show Opening Thursday, April 30 in Novi Presented by Southern Shows 3
... Wound Management,Technologies, Inc., (OTC Bulletin Board: WNDM), announced ... and for 2009. "The company,has been focused on bringing ... 3 quarters of the year to position CellerateRx(TM) as ... We have been working,with several major medical groups, physicians ...
... There is little doubt that Playboy founder Hugh Hefner ... the past half century. From his highly publicized lifestyle ... Hefner has played a leading role in reshaping America,s ... Steven Watts, professor of history in the College of ...
... Sept. 11 A US House Government,Oversight subcommittee ... a mandatory requirement, to reduce mercury emissions. The,Mercury ... at two,congressional hearings over the past several months ... Subcommittee report found that the best way to ...
... Breast Cancer Coalition and celebrate fifteen,years of Education, ... The Pennsylvania,Breast Cancer Coalition (PBCC) Annual Conference ... the Harrisburg Hilton & Towers from 7 a.m. ... of education, advocacy, and research., Pat Halpin-Murphy, ...
... 2008, CHENGDU, China, Sept. 11 /Xinhua-PRNewswire-FirstCall/ ... TYNP), a manufacturer and,supplier of modernized traditional ... announced that the Company has received approval ... (SFDA) to produce Laonian,Kechuan Tablets in the ...
... prominent international awards from the European Society of Cardiology ... treat conditions of the heart. , Professor John Martin, ... Medicine and British Heart Foundation Professor of Cardiovascular Science, ... other holder of this medal in the UK is ...
Cached Medicine News:Health News:Wound Management Technologies, Inc. Announces Strategic Plans for Revenue Growth for Year End and 2009 2Health News:Playboy founder embodies American Dream; changes American culture 2Health News:To Reduce Mercury Pollution, 'Dentists need a mandatory requirement,' According to US House Oversight Report; Mercury Group Concurs 2Health News:Pennsylvania Breast Cancer Coalition Hosts Annual Conference 2Health News:Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Laonian Kechuan Tablets 2Health News:Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Laonian Kechuan Tablets 3Health News:UCL academics awarded prestigious prizes for work on the heart 2
(Date:4/20/2015)... April 20, 2015  Fewer blockbusters drugs are expected ... of opportunities for generic companies in Asia ... are looking beyond the patent cliff to focus on ... Certain established generic manufacturers are restructuring their business models ... molecules, although the impact of these efforts will take ...
(Date:4/20/2015)... PORTLAND, Ore. , April 20, 2015 /PRNewswire/ ... the National Academy of Sciences (PNAS) demonstrates ... & Science University,s Casey Eye Institute ... causes of blindness. Optical coherence tomography (OCT) angiography ... management of these diseases. OHSU researchers ...
(Date:4/20/2015)... 2015 Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK ... the Phase 1 study of MM-302, a novel ... The results were presented today by Patricia LoRusso, ... at the 2015 American Association for Cancer Research ... Data described the safety and promising ...
Breaking Medicine Technology:Generic Drug Companies in Asia Focus More on Market Expansion and Quality, Less on Patent Cliff, Finds Frost & Sullivan 2Generic Drug Companies in Asia Focus More on Market Expansion and Quality, Less on Patent Cliff, Finds Frost & Sullivan 3Generic Drug Companies in Asia Focus More on Market Expansion and Quality, Less on Patent Cliff, Finds Frost & Sullivan 4Generic Drug Companies in Asia Focus More on Market Expansion and Quality, Less on Patent Cliff, Finds Frost & Sullivan 5Study shows new technology may improve management of leading causes of blindness 2Study shows new technology may improve management of leading causes of blindness 3Study shows new technology may improve management of leading causes of blindness 4Study shows new technology may improve management of leading causes of blindness 5Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 2Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 3Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 4Merrimack Announces Final Clinical Results for MM-302 Phase 1 Study Demonstrating Robust Activity in Heavily Pre-Treated Patients with HER2-Positive Metastatic Breast Cancer 5